People: Audentes Therapeutics Inc (BOLD.OQ)

BOLD.OQ on NASDAQ Stock Exchange Global Market

12:28am IST
Change (% chg)

$-1.02 (-3.12%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Schuetz, Thomas 

Dr. Thomas J. Schuetz serves as Co-Founder, Independent Director of the AUDENTES THERAPEUTICS, INC. Dr. Schuetz is currently the Chief Executive Officer of Compass Therapeutics, LLC, a biotechnology company, where he has worked since July 2014. Previously, Dr. Schuetz was a consultant in the biotechnology industry from May 2012 to June 2014, including a consultant for us from July 2012 to June 2013. Prior to consulting, Dr. Schuetz was a venture partner at OrbiMed, a healthcare investment firm, where he worked from November 2007 to May 2012. Dr. Schuetz has also served as the Chief Medical Officer of Therion Biologics Corporation and the Vice President of Clinical Affairs at Transkaryotic Therapies, Inc. (now Shire Pharmaceuticals, Inc.). Dr. Schuetz has served as the Chief Medical Resident at Massachusetts General Hospital and completed a medical oncology fellowship at the Dana-Farber Cancer Institute. Dr. Schuetz previously served on the board of directors of Relypsa, Inc. Dr. Schuetz holds a B.S. from Xavier University, an M.D. from Harvard Medical School and a Ph.D. from Harvard University. Dr. Schuetz is Board Certified in Medical Oncology. Our board of directors believes that Dr. Schuetz’s clinical and executive experience and medical background qualify him to serve on our board of directors.

Basic Compensation

Total Annual Compensation, USD 47,500
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 250,920
Fiscal Year Total, USD 298,420

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --